The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer

PloS One
SeungTaek LimYoung Jin Suh

Abstract

The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis. From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group. Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6-192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy r...Continue Reading

References

Aug 13, 2009·The Breast Journal·Henry G KaplanMary Atwood
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyeong-Gon MoonDong-Young Noh
Jun 25, 2010·Breast Cancer Research and Treatment·Jung Ah LeeUNKNOWN Korean Breast Cancer Society
Nov 15, 2011·Breast Cancer Research and Treatment·L C CollinsA H Partridge
Dec 18, 2012·Breast Cancer Research and Treatment·Junjeong ChoiJa Seung Koo
Mar 16, 2013·The Breast : Official Journal of the European Society of Mastology·Yazan MigdadyAdam J Olszewski
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisNancy U Lin
Oct 17, 2015·Journal of breast cancer·Hyun-Ah KimUNKNOWN Korea Breast Cancer Society
Apr 12, 2016·Journal of breast cancer·Sun Young MinUNKNOWN Korean Breast Cancer Society Consortium
Sep 4, 2016·Breast Cancer Research and Treatment·Jai Min RyuUNKNOWN Korean Breast Cancer Society Consortium
Apr 7, 2017·Journal of breast cancer·Eun Hwa ParkUNKNOWN Korean Breast Cancer Society

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.